Leerink Swann News
-
Kasowitz, Benson, Torres & Friedman LLP hired insurance recovery litigators Jerold Oshinsky and Linda Kornfeld from Jenner & Block LLP as partners to open the firm’s Los Angeles office.
-
Actavis Inc., the largest U.S. maker of generic drugs by market value, agreed to acquire Warner Chilcott Plc for about $5 billion excluding net debt in a deal to expand in women’s health and urology.
-
Two drugs from Bristol-Myers Squibb Co. shrank tumors in as many as half of patients with advanced melanoma, according to early research that may pave the way for cocktails that trigger the immune system to destroy cancer.
-
Actavis Inc. stands to return 17 percent more to shareholders by acquiring birth-control drugmaker Warner Chilcott Plc than selling itself.
-
Teva Pharmaceutical Industries Ltd. resumes trading today in Tel Aviv at the biggest discount to New York in 2 1/2 years after the prospect of acquisitions among generic-drug makers fueled gains in its U.S.-traded stock.
-
Boston Scientific Corp.’s Watchman improved survival in patients with erratic heart rates after four years, an unexpected finding that may help create a $500 million market, said Chief Executive Officer Michael Mahoney.
-
Teva Pharmaceutical Industries Ltd.’s first-quarter profit fell 26 percent as a branded drug lost patent protection and opportunities diminished to introduce new generic medicines.
-
Pfizer Inc., the world’s biggest drugmaker, reduced its 2013 profit forecast after first-quarter sales missed analyst estimates. The shares had their worst one- day loss since August 2011.
-
Jauyo Lee, a former investment banker with Leerink Swann LLC, pleaded guilty to providing inside information about impending mergers involving clients to a college friend who traded on the tips, the U.S. said.
-
Edwards Lifesciences Corp., the biggest-maker of aortic heart valves implanted with a catheter, plunged the most in a dozen years after the company cut its 2013 forecast on slower-than-anticipated sales.
|
|
Most Popular on Bloomberg
|
| |
Rate this Page